Premium
Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo‐controlled trial
Author(s) -
Stapleton John A.,
Sutherland Gay
Publication year - 2011
Publication title -
addiction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.424
H-Index - 193
eISSN - 1360-0443
pISSN - 0965-2140
DOI - 10.1111/j.1360-0443.2010.03274.x
Subject(s) - medicine , varenicline , placebo , nicotine replacement therapy , smoking cessation , randomized controlled trial , nicotine , confidence interval , odds ratio , abstinence , nicotine patch , nasal spray , adverse effect , physical therapy , psychiatry , nasal administration , alternative medicine , pharmacology , pathology
Aims Of six established nicotine replacement therapy (NRT) formulations, only the gum and patch have been tested without specialist clinic support in placebo‐controlled trials. We aimed to broaden the evidence base by examining if the nicotine nasal spray (NNS) could be effective with only brief support in general practice. Design Randomized placebo‐controlled trial. Setting Twenty‐seven English general practices. Participants A total of 761 heavy smokers received brief support and 12 weeks of treatment with NNS (506) or placebo (255). Measurements The primary outcome was biochemically verified complete abstinence from smoking throughout weeks 3–12. Findings NNS compared with placebo more than doubled the number who successfully stopped smoking [15.4% versus 6.7%, odds ratio (OR) = 2.6, 95% confidence interval (CI) = 1.5–4.4]. Many participants reported minor irritant adverse symptoms. NNS was particularly effective among those who were more highly dependent on nicotine (OR = 6.17, 95% CI = 2.13–17.9). Of those who failed to stop during the first week (417, 54.8%), only one (0.2%) achieved later success. Conclusions NNS is effective when given in primary care. The benefit was lower than in a specialist clinic but similar to that with the nicotine patch in primary care. Unlike most other NRT formulations, bupropion or varenicline, NNS was especially helpful for more dependent smokers. Continuing treatment of those initially failing was not beneficial. An initial 1‐week prescription to those more dependent on nicotine is likely to be the most cost‐effective NNS treatment protocol. These results should offer support to the effectiveness of the other NRT formulations untested in this setting.